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In the past ten years, much progress has been made in enlarging the treatment options for B-cell neoplasms due mainly to surface 
targeted therapies. Particularly, the greatest impact 
has been made with monoclonal antibodies (mAbs), 
which bind therapeutically to the relevant target 
antigens causing cell death via several mechanisms. 
Given their success in treating refractory or 
relapsed B-cell neoplasms, mAbs are now included 
in first-line therapy during the induction phase or 
intensification period, as well as during maintenance 
therapy in the post-remission phase of treatment.1,2 
However, as for chemotherapeutic drugs, resistance 
to monoclonal antibody therapy has emerged 
as a limiting factor for the effectiveness of these 
compounds in the treatment of B-cell neoplasms. To 
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العالج املناعي ألورام اخلاليا )B( باستخدام اخلاليا 
)T(املبلورة ملستقبالت هجينة مولدة للمضادات 
من مرحلة اختيار مولد املضاد إىل التطبيقات السريرية
حممد ر�سيد بولع�سل واأحمد جالل
لأورام  حمتمل  كعالج  للم�سادات  مولدة  هجينة  مل�ستقبالت  املبلورة   )T( اخلاليا  با�ستخدام  املناعي  العالج  تقييم  يتم  امللخ�ص: 
اخلاليا)B(. اأظهرت التجارب ال�رسيرية الأخرية نتائج واعدة. وكلما زاد عدد امل�سادات املحتملة للرت�سح، اأ�سبح اختيار امل�ساد املنا�سب 
اأكرث حتديا لت�سميم الدرا�سات ولتقييم اأمثل لفعالية اخلاليا )T( املبلورة للم�ستقبالت الهجينة. املطلوب تقييم دقيق للم�سادات للتاأكد 
من اأن اخلاليا )T( املبلورة للم�ستقبالت الهجينة �سوف تق�سي على اخلاليا اخلبيثة ب�سكل تف�سيلي مع �سمان اأدنى م�ستوى �سمية �سد 
 )T( اخلاليا  لت�سميم  كاأهداف  نظريا  ت�ستعمل  اأن  ميكن  التي  امل�سادات  ملولدات  حمددا  �سطحا   )B( اخلاليا  ُتبلور  الطبيعية.  الأن�سجة 
املبلورة للم�ستقبالت الهجينة. على الرغم من اأن العديد من هذه امل�سادات ميكن اأن حتفز ا�ستجابات خلوية مناعية فعالة داخل اجل�سم 
 )CD19( احلي، فاإن تطبيقاتها ال�رسيرية ماتزال متثل حتديا اإذ اإن امل�سادات الوحيدة التي مت اختبارها يف التطبيقات ال�رسيرية هي
و )CD20(. ن�ستعر�ض هنا مولدات امل�سادات للخاليا )B( لت�سميم امل�ستقبالت الهجينة كما نذكر العقبات التي ميكن اأن تتخلل عملية 
التعرف على الأهداف اخللوية التي ميكن اأن تكون مفيدة.
مفتاح الكلمات: العالج املناعي، خاليا )B(، خاليا )T(، الأورام، امل�ستقبالت الهجينة املولدة للم�سادات.
abstract: Immunotherapy with T cells expressing chimeric antigen receptors (CAR) is being evaluated as a 
potential treatment for B-cell neoplasms. In recent clinical trials it has shown promising results. As the number of 
potential candidate antigens expands, the choice of suitable target antigens becomes more challenging to design 
studies and to assess optimal efficacy of CAR. Careful evaluation of candidate target antigens is required to ensure 
that T cells expressing CAR will preferentially kill malignant cells with a minimal toxicity against normal tissues. 
B cells express specific surface antigens that can theoretically act as targets for CAR design. Although many of 
these antigens can stimulate effective cellular immune responses in vivo, their implementation in clinical settings 
remains a challenge. Only targeted B-cell antigens CD19 and CD20 have been tested in clinical trials. This article 
reviews exploitable B cell surface antigens for CAR design and examines obstacles that could interfere with the 
identification of potentially useful cellular targets.
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overcome these limitations, a variety of approaches 
are being developed to augment the ways by which 
antibodies kill malignant cells.3 
An interesting approach to enforce tumour 
antigen recognition is to generate genetically 
engineered T cells to express highly active chimeric 
antigen receptors (CAR) to kill leukaemic cells 
without the requirement for restriction of the major 
histocompatibility complex (MHC) molecules. 
These genetically engineered T-cell constructs 
combine the antibody-derived antigen-binding 
motif, known as a single-chain fragment of variable 
regions (scFv) that recognises the target antigen, 
with the intracellular functional domains of T-cell 
receptor (TCR)-related signalling molecules, the 
CD3ζ-chain, and T-cell costimulatory molecules 
such as CD28, CD134, and CD137.4,5 Using lentiviral 
transduction or electroporation, the genetic 
constructs are introduced into the autologous 
peripheral T cells collected by leukapheresis 
procedures [Figure 1]. When expressed on T cells, 
CAR redirects T-cell specificity and cytotoxic 
immunoreactivity against the cells expressing 
the targeted antigen epitope.6–8 Generally, before 
an infusion of genetically engineered T cells, 
patients receive lymphodepleting chemotherapy 
to eliminate immunosuppressive cells and other 
lymphoid immune cells that produce growth factors 
such as inteleukin-7 (IL-7) and IL-15.9,10 Current 
protocols suggest that lymphodepletion is required 
to enhance the clinical efficacy of genetically 
engineered T cells.11–13 It has been reported that 
the day of adoptive T-cell transfers in relation to 
preconditioning regimens is critical as T cells given 
at day two after stem cell transplantation show 
superior persistence as compared to those given in 
later days.14 
Until recently, development of this personalised 
T-cell-based therapy was limited due to the lack of 
gene transfer techniques and efficient T-cell culture 
systems. Therefore, previous clinical applications 
with T cells expressing CAR showed modest clinical 
activities, as these engineered T cells demonstrated 
a limited expansion in vivo and rapidly disappeared 
from circulation.6,7,15,16 With the most recent wave 
of genomic technology, great progress has been 
made in improving gene transfer technology and 
in developing methods to enhance T-cell effector 
functions. These advances have made possible the 
creation of second- and third-generation T cells 
expressing CAR, which are endowed with potent 
effector functions.4–8 Thus, several groups have 
evaluated these second generations of CAR as a 
potential treatment to kill leukaemic cells in patients 
with B-cell neoplasms.17-22 
As for any targeted immunotherapy, the 
success of novel genetically engineered T cells 
relies heavily on the characteristics of the target 
cell surface antigen. Since the list of potential 
candidate antigens is expanding, the choice of a 
suitable target becomes more crucial for both the 
design and optimal efficacy of CAR. In addition, 
a critical evaluation of candidate target antigens is 
required to ensure that T cells expressing CAR will 
preferentially kill malignant cells with little toxicity 
against normal tissues. Therefore, this article will 
briefly review the B-cell surface antigens, which 
may be exploited as targets for CAR design to treat 
B-cell neoplasms. It will also examine potential 
obstacles that could interfere with the identification 
of these cellular targets, which might be useful for 
CAR immunotherapy. 
Characteristics of an Ideal 
Target Antigen
An important step in designing a CAR is the 
selection of a good candidate antigen. The target 
antigen should possess certain characteristics to 
justify scientifically its clinical applicability. First, 
the suitable antigen should ideally be expressed 
by malignant cells but not on normal cells. While 
this seems to be a reasonable criterion for antigen 
selection, it may not be a prerequisite in every case, 
especially for B-cell neoplasms where most potential 
targets are also expressed by some cells of normal 
tissues. In these cases, the target antigen should 
be expressed in higher amounts on malignant cells 
relative to normal cells. Second, the target antigen 
should be expressed on the surface of the malignant 
cells. This reasonable cell surface expression is 
important to avoid immune escape of malignant 
cells, which are endowed with a strong predilection 
to down-regulate antigen expression.23 Third, beside 
its immunogenicity, the target antigen should not 
be internalised by malignant cells to ensure the 
induction of immune effector cell functions. Fourth, 
an ideal antigen should exhibit negligible shedding 
and only a small amount of secretion with a limited 
potential for mutation to avoid compromising its 
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surface molecule exclusively expressed by B cells 
and follicular dendritic cells among cells of the 
hematopoietic system.25,26 Of interest, its expression 
is lost during terminal B-cell differentiation 
into plasma cells. CD19 is involved in growth 
regulation of B cells through the B-cell antigen 
receptor. It is also required for the development of 
marginal zone B cells, germinal centre formation, 
T-dependent antibody response, and B-cell memory 
maintenance.26 Compared to other B-cell surface 
molecules, CD19 is expressed at high levels on 
essentially all B-lineage leukaemias and lymphomas, 
making this antigen an excellent tumour-associated 
antigen for CAR development. 
CD20 ANTIGEN
Following the identification of surface 
immunoglobulin, CD20 was the first cell surface 
differentiation antigen of human B cells to be 
identified by a monoclonal antibody. CD20 is a 
33-37-kDa integral membrane protein with four 
transmembrane domains and an extracellular 
disulfide bond.27 It is expressed on pre-B and 
mature naïve B cells but not on plasma cells or early 
pro-B cells. At the primary sequence level, CD20 
shows little sequence homology with CD19 but 
therapeutic utility. Finally, the antigen of interest 
should preferentially be involved in key functions of 
the target cell such as growth-regulating signalling, 
immune recognition, or apoptosis. 
Potential Candidate 
Antigens for CAR Design 
in B-Cell Neoplasms 
B cells express a variety of specific surface antigens 
that can theoretically act as targets for CAR 
design. Although many of these antigens showed 
the ability to stimulate effective cellular immune 
responses in vivo, their implementation in clinical 
settings remains a big challenge. The ones with the 
most promise in B-cell neoplasms are summarised 
in Figure 2, and their characteristics are briefly 
described in Table 1. 
CD19 ANTIGEN
Because of its promising proprieties in B-cell 
development, pioneering work in CAR design 
focused on the CD19 antigen. This molecule 
was first identified as the B4 antigen on normal 
and malignant human B lymphocytes.24 This 95-
kDa type I transmembrane glycoprotein is a cell 
Figure 1: Clinical application of T cells expressing chimeric antigen receptors. Following a leukapheresis procedure, 
autologous T cells are isolated, transduced with a lentiviral vector and re-infused to patient after lymphodepletion with 
chemotherapy.
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both antigens interact with MHC class II molecules 
on B cells. Current studies suggest that CD20 is a 
component of a signal transduction complex that is 
involved in the growth regulation of B lymphocytes 
following activation.28 In addition to its restricted 
B-lineage expression, CD20 is present on the 
majority of B-cell lymphomas, providing a strong 
rationale for CAR design. 
CD22 ANTIGEN
The CD22 antigen was originally identified as a 
B-cell-associated adhesion molecule that appears to 
function in the regulation of B-cell activation. It is a 
member of the sialic-acid binding immunoglobulin-
like lectin (SIGLEC) family. SIGLEC proteins are 
a subset of the immunoglobulin super-family of 
cell recognition molecules that bind to sialic acid-
containing glycans of the cell surface.29 CD22 is 
a 135-140-kDa B-cell-specific transmembrane 
sialoglycoprotein, expressed on all B cells except 
on memory B cells and plasma cells.30 It regulates 
multiple B-cell functions including the cellular 
activation thresholds and survival. In this role, CD22 
modulates B-cell dependent immune responses, 
prevents autoimmunity, and controls the homing of 
B cells back to the bone marrow. It also modulates 
T-cell signalling upon binding to its ligand on 
T cells.31 CD22 is strongly expressed by many 
B-cell lymphomas and leukaemias, particularly 
hairy cell leukaemia, where it is universally highly 
expressed.32 Given that CD22 is found on normal 
B cells at low levels but not on plasma cells, these 










CD19 95-kDa glycoprotein All B cells except 
plasma cells




CLL FL SMZL 
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All B cells except 
plasma cells and 
early pro-B cells






All B cells except 
plasma cells and 
memory B cells
Raji, Daudi and 
Ramos B cell lines
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CD23 45-kDa glycoprotein All B cells except 
immature bone 
marrow B cells
MEC-1 CLL, BJAB 














 All B cells ND ND 41
CD70 50-kDa glycoprotein Activated B cells Raji, Daudi, CLL-
120, 239T, U266 





 All B cells ND ND 44
CD80 60-kDa glycoprotein Activated B cells ND ND 47
Igκ light 
chain
25-kDa glycoprotein  All B cells Raji, Daudi, BJAB 
CLL-120, SP-53 and 
K562 cell lines SCID 
mice
ND 60
Legend: Raji, Daudi and Ramos = Human Burkitt's lymphoma cell line; SCID = severe combined immunodeficient; NOD = non-obese diabetic; 
MB185 = mouse pre-B cell lymphoma cell line; MEC-1 CLL and CLL-120 = chronic lymphocytic leukemia cell line; BLAB = B-lymphoblastoid cell 
line; JeKo-1 = mantle cell lymphoma cell line; 293T = human embryonic kidney cell line; U266 = myeloma cell line; K562= human erythroleukaemic 
cell line; SP-53 = lymphoma cell line; CLL = chronic lymphocytic leukaemia; FL = follicular lymphoma; SMZL = splenic marginal zone lymphoma; 
B-ALL = B-cell acute lymphoblastic leukaemia; MCL = mantle cell lymphoma; ND = not determined. 
Mohamed-Rachid Boulassel and Ahmed Galal
review | 277
on activated monocytes and eosinophils. The 
expression of CD30 is highly induced on B cells by 
mitogen activators, or as a result of viral infection 
with human T-cell lymphotropic viruses (HTLV), 
human immunodeficiency virus (HIV), or EBV.37 
Of interest is the finding that CD30 expression is 
absent on most cells outside the immune system. 
Interaction of CD30 with its ligand CD153 induces 
the recruitment of signalling proteins, which leads 
to the transduction of several biological signals 
such as cell death, proliferation, activation, and 
differentiation depending on the cellular context.37 
In addition to the malignant disorders cited above, 
CD30 is also expressed on 20% of B-cell lymphomas 
and some multiple myeloma cells. Thus, because 
of its restricted profile expression in normal 
conditions, the CD30 antigen appears to be an 
attractive target for CAR development. 
CD40 ANTIGEN
Like CD30, the CD40 antigen belongs to the TNFR 
superfamily and is a surface receptor of 45-50-
kDa, playing a central role in T-cell-dependent 
B-cell activation and proliferation36 CD40 is 
expressed during all stages of B-cell development 
and differentiation, whereas its ligand (CD40L 
or CD154) is mainly expressed on activated T 
cells. In addition to its expression on all antigen-
presenting cells such as dendritic cells, follicular 
dendritic cells, and monocytes, CD40 is also 
expressed on non-haematopoietic cells including 
endothelial cells, fibroblasts, and epithelial cells.38 
In fact, CD40 is involved in the amplification and 
regulation of inflammatory responses by providing 
critical signals required for the optimal activation of 
immune cells. These key signals resulted in optimal 
antigen presentation, expansion of antigen-specific 
memory and effector T cells, proliferation of B-cell 
responses, immunoglobulin class switching, and 
secretion of cytokines.39 Currently, the CD40-
CD40L immunostimulatory effect is used to 
enhance antigen presentation in gene transfer 
protocols. High levels of CD40 expression were 
detected on a wide range of malignant cells including 
B-cell neoplasms, bladder cells, and carcinoma cell 
types, among others. It has been reported that in 
Hodgkin’s lymphoma, hairy cell leukaemia, chronic 
lymphocytic leukaemia, and follicular lymphomas, 
CD40 activation contributed to tumour survival 
and resistance to chemotherapy. In HIV-related 
characteristics make CD22 an attractive target for 
CAR development.
CD23 ANTIGEN
The CD23 antigen was initially defined as the 
low-affinity receptor for immunoglobulin (Ig)-E, 
also known as FcεRII. It is a 45-kDa type II 
transmembrane glycoprotein expressed on B cells 
but not on immature bone marrow B lymphocytes. 
Its expression was also reported on various cell types 
including monocytes, eosinophils, and platelets.33 
CD23 participates in multiple regulatory functions 
either as a membrane-bound glycoprotein or as a 
freely soluble protein. Among these functions, CD23 
regulates the production of immunoglobulin-E, the 
antibody that mediates the allergic reactions, and 
B-cell growth, as underlined by its overexpression 
and abnormal regulation in two B-cell neoplasms 
resulting from the clonal expansion of mature 
B cells (i.e. chronic lymphocytic leukaemia and 
small cell lymphocytic lymphoma).34 In addition, 
the Epstein-Barr virus (EBV)-transformed B cells 
express high levels of CD23 and its expression is 
used to delineate classical Hodgkin’s lymphoma 
from mediastinal diffuse large lymphoma.34 In 
combination, these properties support CD23 
credibility as an interesting target for CAR design 
in B-cell neoplasms. 
CD30 ANTIGEN
Based on its presence on Reed-Sternberg cells, 
which are characteristic of Hodgkin’s lymphoma, 
CD30 was identified by means of the monoclonal 
antibody Ki-1 in 1982. Since then, CD30 has 
been used as a diagnostic marker for Hodgkin’s 
lymphoma and allowed the description of a new 
group of malignant disorders named CD30-positive 
lymphoproliferative disorders.35 The CD30 antigen 
is a member of the tumour necrosis factor receptor 
(TNFR) superfamily which includes CD40, CD70, 
CD95, and CD134, among others.36 CD30 is a 
type I glycoprotein with a molecular weight of 
102-120-kDa. Structurally, an 85-kDa form, which 
is a product of the proteolytic cleavage of the 
CD30 antigen, could be detected in the blood of 
patients with CD30-positive lymphoproliferative 
disorders or autoimmune diseases.37 Under 
normal conditions, CD30 expression is detected 
in activated B, T and natural killer cells. In 
addition, lower levels of expression were reported 
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lymphomas, CD40 binding triggered the growth 
of B cells via the activation of the nuclear factor-
kappa-B (NF-κB) pathway that in turn stimulated 
HIV replication.38,39 Because of the key role of 
CD40 in mediating growth of B-cell neoplasms, 
this antigen could be a promising target for CAR 
development.
CD52 ANTIGEN
The CD52 antigen, also known as the Cambridge 
pathology (CAMPATH)-1 antigen, is a surface 
glycoprotein with a molecular weight of 21-28-
kDa. CD52 comprises a short peptide sequence of 
twelve amino acids and a large complex N-linked 
oligosaccharide, and is attached to the cellular 
membrane by a glycosylphosphatidylinositol 
(GPI) anchor.40 It is abundantly expressed on 
virtually all B and T lymphocytes and, to a lesser 
degree, on monocytes and natural killer cells. It is 
also expresses on a large proportion of lymphoid 
B-cell malignancies including lymphomas and 
chronic lymphocytic leukaemia.41 The response 
of B lymphocytes, following its activation via the 
CD52 antigen, varies according to both the state 
of cellular maturation and the way the antigen is 
presented to cells and results in clonal expansion, 
differentiation, anergy, or deletion by apoptosis. It 
has been reported that the cross-linking of CD52 on 
B-cell lines resulted in profound growth inhibition, 
corroborating the notion that this antigen might be 
used as a target for CAR design.  
CD70 ANTIGEN
The CD70 antigen is a member of the TNFR 
superfamily, like the CD30 and CD40 antigens.36 
CD70 is a type II transmembrane glycoprotein 
with a molecular weight of 50-kDa. It is transiently 
expressed by activated T and B lymphocytes, 
monocytes, and dendritic cells. It is also expressed 
on stromal thymic cells of the medulla, but not on 
other normal cells or tissues.42 The interaction of 
CD70 with its ligand CD27 regulates the expansion 
and differentiation of memory and effector T cells 
whereas in B cells, CD70-CD27 co-stimulation 
promotes B-cell expansion through several 
signalling pathways including spleen tyrosine 
kinase, phosphoinositide 3-kinase, and NF-κB.43 
Of interest, CD70 expression is documented in 
many different types of lymphomas, leukaemias, 
and carcinomas. CD70 is abundantly expressed by 
B-cell derived non-Hodgkin lymphoma including 
diffuse large B-cell lymphoma, follicular lymphoma, 
Burkitt’s and mantle cell lymphomas, and B-cell 
lymphocytic leukaemia as well as Waldenström 
macroglobulinaemia, multiple myeloma, and 
chronic lymphocytic leukaemia.42 It is also highly 
Figure 2: B-cell surface antigens that may be exploited as potential targets for chimeric antigen receptor design.
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includes CD80-, CD86-, B7-H3, B7-H4, the 
inducible costimulator ligand, and the programmed 
death-1 and death-2 ligands.46 These molecules are 
transmembrane, or glycosyl-phosphatidylinositol 
(GPI)-linked proteins, playing key roles in immune 
responses by providing co-stimulatory or co-
inhibitory signals upon binding their receptor. 
In addition to its well-known role in regulating 
T-cell activity, recent studies suggest that CD80 
also regulates B-cell functions.47 Cross-linking of 
CD80 on lymphoma cell lines resulted in growth 
inhibition and up-regulation of pro-apoptotic 
molecules.48 CD80 is transiently expressed on the 
surface of activated B cells but is constitutively 
expressed on a variety of non-Hodgkin lymphomas, 
including follicular lymphoma, making it a good 
target for CAR design.  
Immunoglobulin Light 
Chains
Another potential antigen for CAR design is the 
kappa (κ) light chain (LC) of the Ig molecules. Ig 
is formed by two identical heavy chains and two 
identical LCs, lambda (λ) and κ. B lymphocytes 
express surface monoclonal Igs with either κ or λ 
light chains. Since expression of λ/κ LCs is clonally 
restricted, and B-cell neoplasms such as low-grade 
non-Hodgkin lymphoma and chronic lymphocytic 
leukaemia are themselves clonal, the malignant cells 
in a given patient will express either κ or λ LC.49 
Therefore, targeting the LC expressed by malignant 
B-cells should spare the normal population of B 
lymphocytes that express the reciprocal LC. Thus, 
LC λ or κ  may be considered an attractive antigen 
for CAR development. 
Improving the Clinical 
Applicabil ity of Targeted 
Antigens for Designing 
CAR
As discussed above, several candidate antigens 
can be targeted for designing CAR. These 
antigens are typically normal cell constituents 
that are over-expressed in B-cell neoplasms. The 
potential contribution of each antigen to CAR 
development and implementation is still debated. 
For instance, what determines which antigens 
should be first targeted? An additional question 
expressed on Reed-Sternberg cells in Hodgkin’s 
lymphoma and other non-lymphoid tumour cells 
such as nasopharyngeal carcinoma, astrocytoma, 
glioblastoma, and renal cell carcinoma (RCC) as well 
as in EBV- and HTLV-associated malignancies.42 
Given the differential expression pattern of CD70 
in leukaemic cells as compared to normal B cells, 
this antigen represents a prominent target for CAR 
development.
CD74 ANTIGEN
The CD74 antigen, also known as an invariant chain 
(Ii), is a conserved type II membrane glycoprotein 
with a molecular weight of 31-41-kDa. The Ii on the 
cell surface is present in four isoforms and controls 
several aspects of the immune system.44 In addition 
to its role as a chaperone molecule for MHC class 
II molecules, CD74 is involved in several signalling 
pathways. CD74 is fundamental to the correct 
folding and transport of MHC class II molecules 
to endosomes and lysosomes as well as in antigen 
loading. It is directly involved in the maturation 
of B cells through the NF-κB pathway.44 It also 
serves as the high-affinity receptor for the pro-
inflammatory cytokine known as the macrophage 
migration inhibitory factor, which activates innate 
immune cells such as macrophages and monocytes 
through kinase signalling pathways.44 Under 
normal conditions, CD74 is expressed on MHC 
class II positive cells such as B cells, monocytes, 
macrophages, thymic epithelium, Langerhans 
cells, activated T cells and dendritic cells. Under 
the inflammatory processes, CD74 is also detected 
in high levels on endothelial and epithelial cells as 
well as on a variety of malignant cells.45 Its over-
expression is observed in several forms of cancer 
and many B-cell neoplasms, including non-Hodgkin 
lymphoma, chronic lymphocytic leukaemia, 
multiple myeloma, and follicular lymphoma. In 
many of these cancers, increased CD74 expression 
is associated with tumour progression and poor 
clinical outcomes.45 Compared to normal tissue, the 
relatively high expression of CD74 combined with 
the rapid internalisation of CD74 on ligation makes 
it an attractive target for CAR design. 
CD80 ANTIGEN
Among other potential antigens for CAR design 
is CD80, a 60-kDa transmembrane glycoprotein. 
This antigen is a member of the B-family that 
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is which B-cell neoplasms should be studied first? 
In this regard, defining shared features of target 
antigens is of paramount importance in designing 
and implementing CAR in B-cell neoplasms. CAR 
targeting CD19 (CART19) and CD20 (CART20) 
antigens were the first molecules to be used in 
B-cell malignancies. In early ex vivo studies, both 
T cells expressing CAR19 (CART19) and CART20 
efficiently lysed a wide panel of tumour cell lines 
expressing CD19 and CD20 antigens, respectively, 
as well as B cells freshly isolated from patients 
with B-cell neoplasms.50–56 In animal models, 
CART19 and CART20 also eradicated systemic 
cell tumours established in severe combined 
immunodeficient (SCID) mice that were expressing 
CD19 or CD20.51,52 These preclinical experiments 
have supported the notion that under appropriate 
conditions, T cells can be therapeutically redirected 
to eliminate malignant B cells and have justified the 
translation of these genetically engineered T cells 
to clinical settings. Recently, in proof of principle 
studies, adoptive transfer of CART19 or CART20 
to patients with chemotherapy-refractory chronic 
lymphocytic leukaemia or follicular lymphoma 
demonstrate encouraging results in terms of 
reducing the leukaemic B-cell burden.17–22 Taken 
together, CART19- and CART20-based clinical 
trials are at the advanced planning stage in several 
centres around the world, and the results of these 
will be of importance to further establish the clinical 
efficacy of this therapeutic approach. Other CAR-
targeting CD22 (CART22), CD23 (CART23), and 
CD70 (CART70) antigens as well as κ LC (CARTκ) 
were also developed showing promising results in 
in vitro and in vivo mouse tumour models.57–60 
With respect to the therapeutic potential of 
tested CAR, it is worthwhile to note that suboptimal 
cytotoxic effects of these genetically engineered 
T cells vary among targeted antigens. Although 
several explanations may be proposed, one possible 
reason is the difference in expression levels of the 
targeted antigens in malignant and normal B cells. 
For example, it has been reported that normal B 
cells express high levels of CD20 when compared to 
CD22, with copy numbers per cell of approximately 
150 x 103 and 30 x 103, respectively.61,62 This high 
antigen intensity of CD20 on B cells may lead 
to anergy or deletion of engineered T cells, as 
demonstrated in adoptively transferred antigen-
specific T cells in transgenic mice.63 Malignant B 
cells also showed a substantial variability over time 
in the expression intensity of different targeted 
antigens. The expression levels of targeted antigens 
on B cells may vary according to type of B-cell 
neoplasms, stage of the disease, and also from 
patient to patient.61,62,64 Thus, it is of importance 
that optimisation of CAR design benefits from the 
quantification of information about expression 
levels of targeted antigens on malignant B cells 
for each patient to increase anti-tumour activities. 
Therefore, the challenge now is to develop methods 
that can precisely measure the expression levels of 
targeted antigens on malignant and normal B cells 
in an accurate and reproducible way. Additionally, 
these standardised methods should be suited to 
clinical settings, easy to run, and non-invasive. 
One such method is flow cytometry, a robust and 
well-established technique that is regarded as an 
excellent immunophenotyping tool, as multiple 
molecules and surface antigens can be detected 
in individual cells.65 At present, it is not known to 
what extent heterogeneous antigen expression by 
individual malignant B cells represents a problem 
for CAR immunotherapy. However, it is quite 
likely that malignant B cells with low levels of 
targeted antigens may escape immunotherapy with 
engineered T cells. Since the targeted antigens 
are distinct molecules, the possibility exists for 
combining CART19 or CART20 with CART22, 
CART23, CART70, or CARTκ potentially to yield 
additive or synergistic activities against malignant 
B cells. In addition, to eliminate completely all 
malignant B cells, effective immunotherapy with 
CAR requires targeting surface antigens, which 
are expressed with great specificity by the earliest 
leukaemic progenitor. In this regard, engineered T 
cells should successfully penetrate deeper into the 
tissue and home to the sites with residual leukaemic 
B cells. Besides their capacity to proliferate and 
survive in vivo, the efficacy of engineered T cells 
to eradicate residual leukaemic B cells may also be 
dependent on the choice of the epitope targeted 
by the potential antigens. Clearly, the position of 
the targeted epitope itself, particularly its position 
within the antigen, has a major impact on the efficacy 
of engineered T cells activation independent of the 
scFv binding efficiency.66
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Long term Potential 
Toxicities of Targeted B 
Cell Antigens
In order to establish T cells expressing CAR as an 
effective immunotherapy for B-cell neoplasms, 
several issues still need to be overcome. Some of 
these issues include the long-term potential toxicity 
to normal cells, long half-life, potential cross-
reactivity, immuno-toxicity, and genotoxicity of 
CAR.
TOXICITY TO NORMAL 
CELLS 
An important concern with T cells expressing 
CAR is the long-term toxicity resulting from 
the depletion of normal human cells, which are 
important for homeostatic functions. This toxicity 
depends mainly on the distribution of the targeted 
antigens in normal tissues, as recently demonstrated 
in a clinical trial using T cells expressing CARG250 
(CARTG250), a prominent RCC antigen.67 In early 
studies, monoclonal antibodies against this antigen 
showed a good safety profile in patients with RCC, 
but when scFv specificity was tested in CARTG250, 
severe hepatotoxicity occurred due to the reactivity 
of engineered T cells against the G250 antigen 
expressed at very low levels on the biliary epithelium. 
Similarly, based on the widely used humanised mAb 
trastuzumab in cancer patients, a third generation 
of T cells expressing CAR was developed against 
the tumour antigen ERBB2. The genetically 
engineered T cells displayed a robust anti-tumour 
activity in animal models, but strongly reacted 
with the ERBB2 antigen expressed at low levels on 
lung epithelial cells, resulting in sudden death of 
the patient five days after treatment.68 Collectively, 
these results demonstrate that the safety of targeted 
antigens with mAbs does not translate into the 
safety of T cells expressing CAR because these 
engineered T cells with high-avidity receptors can 
respond to cells expressing their targeted antigens 
at levels too low to be detected with conventional 
means. Although in B cell neoplasms, depletion 
of normal B cells following an engineered T-cell 
infusion could be medically managed by Ig transfer 
and antiviral drugs, the potential risk of a negative 
impact on other organ functions due to low levels 
of antigen expression should be carefully evaluated.
LONG HALF-LIFE
The issue of the long half-life of T cells expressing 
CAR remains a major problem. Unlike mAbs, 
which have defined half-lives, engineered T cells 
may potentially survive and function for years. 
Therefore, the risks versus benefits should be 
clearly balanced for any given patient and a given 
CAR design. As a cautionary note, early therapy 
with CART19 resulted in the death of a patient who 
was suffering from chronic lymphocytic leukaemia 
with a cytokine storm, supporting further the direct 
cytotoxic potency of these engineered T cells.69 
POTENTIAL CROSS-
REACTIVITY
The possibility of unwanted cross-reactivity is 
becoming increasingly important in CAR design. 
Engineered T cells may react with more than 
one antigenic determinant if some modifications 
occur when transfecting these T cells with viral 
vectors. This cross-reactivity may arise because the 
targeted antigens share an epitope with other tissue 
antigens, or because they have an epitope which 
is structurally similar to one used for designing 
CAR. It may also result from an epitope or antigen 
spreading, a process in which engineered T cells 
may expand their immune responses beyond the 
primary epitope to target other epitopes on normal 
cells. While these cross-reactivities are difficult to 
predict, they may lead to severe toxicity, especially 
since new targeted antigens are being evaluated with 
second or third generations of CAR. These latter are 
endowed with potent cytotoxic activities by killing 
cells which express just a few antigen molecules. 
POTENTIAL 
IMMUNOTOXICITY 
A key issue for the use of engineered T cells is the 
potential immunotoxicity of CAR. It has recently 
been reported that immune responses against 
both viral vector and scFv binding epitopes can 
be detected in patients receiving engineered T 
cells.70,71As a consequence, these immune responses 
may compromise the persistence of engineered T 
cells and also limit their anti-tumour activities. It 
is therefore essential to monitor carefully a host’s 
immune responses against all transgene products, 
including vectors themselves in order to increase 
the efficacy of engineered T cells.  
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POTENTIAL GENOTOXICITY 
Insertion of suicide genes into the protein 
constructs could be envisaged to further limit 
long-term CAR toxicities. However, introduction 
of genetic material may lead to genotoxicity; that 
considered, so far there has been no reported 
evidence that retrovirally engineered mature T cells 
induce mutagenesis.72,73 Since their first description, 
engineered T cells have been used in more than one 
hundred patients with no malignant transformation 
reported in any case, contrasting with what was 
observed with genetically modified haematopoietic 
stem cells.74 To mitigate CAR toxicities, approaches 
such as a dose-escalating strategy or splitting 
T-cell doses over two or more days may be applied, 
particularly when new targeted antigens are first 
evaluated.8,75Another approach is to administer 
high-dose corticosteroids, which could effectively 
eliminate engineered T cells as was demonstrated 
in RCC patients receiving CARTG250.67 
Conclusion
As engineered T-cell designs continue to improve, 
the selection of therapeutic targeted antigens 
has become crucial to the development of CAR. 
Lessons learned so far from pilot clinical trials in 
patients treated with T cells expressing CAR clearly 
emphasise the importance of the choice of the 
right antigen. Intense investigation is underway to 
discover more candidate antigens not only to expand 
the repertoire of potential targets for CAR design 
but also to identify those antigens that will provide 
selected killing of malignant B cells while sparing 
normal lymphocytes. A critical issue remains in 
identifying those targeted antigens that could 
be specifically expressed on B cells in individual 
neoplasms but not necessarily be used across all 
categories of patients with B cell malignancies.
By further understanding the characteristics of 
potential targeted antigens, it may be possible to 
identify key epitopes that will help design new CAR 
with the goal of providing maximal clinical efficacy 
of engineered T cells. It might also be expected that 
multiple antigenic epitopes could be combined and 
targeted to further improve the killing properties of 
CAR therapy. 
Equally important, research should also focus 
on identifying subsets of patients who are likely 
to respond to a specific target antigen. This will 
provide a rational basis for target antigens to be 
exploited in well-designed multicentre studies to 
establish engineered T-cell immunotherapy as a 
viable option in the treatment of B-cell neoplasms. 
One might also argue that the selection of T-cell 
populations that could be used for CAR design, 
conditioning regimens, and infused T-cell doses 
may be different for each targeted antigen. Thus, it 
is quite possible that the only improvements in all 
these aspects will lead to significant progress that 
will ultimately advance the field of CAR therapy. 
This will require collaboration across different 
academic groups representing different disciplines 
in order to provide faster information that could 
be quickly translated into the CAR design. In the 
meantime, it is hoped that ongoing clinical trials 
will continue to generate increasing enthusiasm for 
the application of this personalised T-cell-based 
immunotherapy in B-cell neoplasms.
ACkNOwLEDGMENT
The authors are grateful to Rhyan Pineda for 
technical assistance in drawing the figures. 
CONFLICT OF INTEREST 
None. 
References
1. Chamuleau ME, van de Loosdrecht AA, Huijgens 
PC. Monoclonal antibody therapy in haematological 
malignancies. Curr Clin Pharmacol 2010; 5:148–59.
2. Cartron G, Watier H, Golay J, Solal-Celigny P. From 
the bench to the bedside: Ways to improve rituximab 
efficacy. Blood 2004; 104:2635–42. 
3. Quintás-Cardama A, Wierda W, O’Brien S. 
Investigational immunotherapeutics for B-cell 
malignancies. J Clin Oncol 2010; 28:884–92.
4. Cartellieri M, Bachmann M, Feldmann A, Bippes 
C, Stamova S, Wehner R, et al. Chimeric antigen 
receptor-engineered T-cells for immunotherapy of 
cancer. J Biomed Biotechnol 2010; 2010:956304. 
5. Kohn DB, Dotti G, Brentjens R, Savoldo B, Jensen M, 
Cooper LJ, et al. CARs on track in the clinic. Mol 
Ther 2011; 19:432–8.
6. Jena B, Dotti G, Cooper LJ. Redirecting T-cell 
specificity by introducing a tumor-specific chimeric 
antigen receptor. Blood 2010; 116:1035–44.
7. Sadelain M, Brentjens R, Rivière I. The promise and 
potential pitfalls of chimeric antigen receptors. Curr 
Opin Immunol 2009; 21:215–23.
Mohamed-Rachid Boulassel and Ahmed Galal
review | 283
8. Ertl HC, Zaia J, Rosenberg SA, June CH, Dotti 
G, Kahn J, et al. Considerations for the clinical 
application of chimeric antigen receptor T cells: 
Observations from a recombinant DNA Advisory 
Committee Symposium held June 15, 2010. Cancer 
Res 2011; 71:3175–81.
9. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony 
PA, Palmer DC, Spiess PJ, et al. Removal of 
homeostatic cytokine sinks by lymphodepletion 
enhances the efficacy of adoptively transferred 
tumor-specific CD8+ T cells. J Exp Med 2005; 
202:907–12. 
10. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, 
Kammula U, et al. Adoptive cell therapy for patients 
with metastatic melanoma: evaluation of intensive 
myeloablative chemoradiation preparative regimens. 
J Clin Oncol 2008; 26:5233–9. 
11. Cui Y, Zhang H, Meadors J, Poon R, Guimond 
M, Mackall CL. Harnessing the physiology of 
lymphopenia to support adoptive immunotherapy in 
lymphoreplete hosts. Blood 2009; 114:3831–40. 
12. Wrzesinski C, Paulos CM, Kaiser A, Muranski P, 
Palmer DC, Gattinoni L, et al. Increased intensity 
lymphodepletion enhances tumor treatment efficacy 
of adoptively transferred tumor-specific T cells. J 
Immunother 2010; 33:1–7.
13. Muranski P, Boni A, Wrzesinski C, Citrin DE, 
Rosenberg SA, Childs R, et al. Increased intensity 
lymphodepletion and adoptive immunotherapy-
-how far can we go? Nat Clin Pract Oncol 2006; 
3:668–81.
14. Rapoport AP, Stadtmauer EA, Aqui N, Vogl D, Chew 
A, Fang HB, et al. Rapid immune recovery and graft-
versus-host disease-like engraftment syndrome 
following adoptive transfer of costimulated 
autologous T cells. Clin Cancer Res 2009; 15:4499–
507. 
15. Brocker T, Karjalainen K. Signals through T-cell 
receptor-zeta chain alone are insufficient to prime 
resting T lymphocytes. J Exp Med 1995; 181:1653–9.
16. Brocker T. Chimeric Fv-zeta or Fv-epsilon receptors 
are not sufficient to induce activation or cytokine 
production in peripheral T cells. Blood 2000; 
96:1999–2001. 
17. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, 
Greisman HA, et al. Adoptive immunotherapy for 
indolent non-Hodgkin lymphoma and mantle cell 
lymphoma using genetically modified autologous 
CD20-specific T cells. Blood 2008; 112:2261–71. 
18. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, 
Stetler-Stevenson M, Feldman SA, et al. Eradication 
of B-lineage cells and regression of lymphoma in a 
patient treated with autologous T cells genetically 
engineered to recognise CD19. Blood 2010; 
116:4099–102. 
19. Porter DL, Levine BL, Kalos M, Bagg A, June CH. 
Chimeric antigen receptor-modified T cells in 
chronic lymphoid leukemia. N Engl J Med 2011; 
365:725–33. 
20. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, 
Bagg A, et al. T cells with chimeric antigen receptors 
have potent antitumor effects and can establish 
memory in patients with advanced leukemia. Sci 
Transl Med 2011; 3:95ra73.
21. Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, 
Stefanski J, et al. Safety and persistence of adoptively 
transferred autologous CD19-targeted T cells in 
patients with relapsed or chemotherapy refractory 
B-cell leukemias. Blood 2011; 118:4817–28.
22. Kochenderfer JN, Dudley ME, Feldman SA, Wilson 
WH, Spaner DE, Maric I, et al. B-cell depletion 
and remissions of malignancy along with cytokine-
associated toxicity in a clinical trial of anti-CD19 
chimeric-antigen-receptor-transduced T cells. Blood 
2012; 119:2709–20. 
23. Lollini PL, Forni G. Cancer immunoprevention: 
Tracking down persistent tumor antigens. Trends 
Immunol 2003; 24:62–6. 
24. Nadler LM, Anderson KC, Marti G, Bates M, Park E, 
Daley JF, et al. B4, a human B lymphocyte-associated 
antigen expressed on normal, mitogen-activated, 
and malignant B lymphocytes. J Immunol 1983; 
131:244–50.
25. Schriever F, Freedman AS, Freeman G, Messner 
E, Lee G, Daley J, et al. Isolated human follicular 
dendritic cells display a unique antigenic phenotype. 
J Exp Med 1989; 169:2043–58. 
26. Tedder TF. CD19: A promising B cell target for 
rheumatoid arthritis. Nat Rev Rheumatol 2009; 
5:572–7. 
27. Tedder TF, Engel P. CD20: A regulator of cell-cycle 
progression of B lymphocytes. Immunol Today 1994; 
15:450–4. 
28. Ernst JA, Li H, Kim HS, Nakamura GR, Yansura DG, 
Vandlen RL. Isolation and characterisation of the 
B-cell marker CD20. Biochemistry 2005; 44:15150–
8.
29. Crocker PR, Paulson JC, Varki A. SIGLECs and their 
roles in the immune system. Nat Rev Immunol 2007; 
7:255–66.
30. Tedder TF, Tuscano J, Sato S, Kehrl JH. CD22, a 
B lymphocyte-specific adhesion molecule that 
regulates antigen receptor signaling. Annu Rev 
Immunol 1997; 15:481–504. 
31. Walker JA, Smith KG. CD22: An inhibitory enigma. 
J Immunol 2008; 123:314–25. 
32. Robbins BA, Ellison DJ, Spinosa JC, Carey CA, 
Lukes RJ, Poppema S, et al. Diagnostic application of 
two-color flow cytometry in 161 cases of hairy cell 
leukemia. Blood 1993; 82:1277–87. 
33. Bonnefoy JY, Lecoanet-Henchoz S, Gauchat JF, 
Graber P, Aubry JP, Jeannin P, et al. Structure and 
functions of CD23. Int Rev Immunol 1997; 16:113–
28. 
Immunotherapy for B-Cell Neoplasms using T Cells expressing Chimeric Antigen Receptors  
From antigen choice to clinical implementation
284 | SQU Medical Journal, August 2012, Volume 12, Issue 3
34. Acharya M, Borland G, Edkins AL, Maclellan 
LM, Matheson J, Ozanne BW, et al. CD23/FcεRII: 
Molecular multi-tasking. Clin Exp Immunol 2010; 
162:12–23.
35. Pinter-Brown LC. SGN-30: A basis for the effective 
treatment of CD30 positive hematopoietic 
malignancies. Expert Opin Investig Drugs 2008; 
17:1883–7.
36. Rickert RC, Jellusova J, Miletic AV. Signaling by the 
tumor necrosis factor receptor superfamily in B-cell 
biology and disease. Immunol Rev 2011; 244:115–33.
37. Gerber HP. Emerging immunotherapies targeting 
CD30 in Hodgkin‘s lymphoma. Biochem Pharmacol 
2010; 79:1544–52. 
38. van Kooten C, Banchereau J. CD40-CD40 ligand. J 
Leukoc Biol 2000; 67:2–17
39. Tong AW, Stone MJ. Prospects for CD40-directed 
experimental therapy of human cancer. Cancer Gene 
Ther 2003; 10:1–13.
40. Treumann A, Lifely MR, Schneider P, Ferguson 
MA. Primary structure of CD52. J Biol Chem 1995; 
270:6088–99. 
41. Gilleece MH, Dexter TM. Effect of Campath-1H 
antibody on human hematopoietic progenitors in 
vitro. Blood 1993; 82:807–12.
42. Boursalian TE, McEarchern JA, Law CL, Grewal IS. 
Targeting CD70 for human therapeutic use. Adv Exp 
Med Biol 2009; 647:108–19. 
43. Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T 
cell and B cell activation. Curr Opin Immunol 2005; 
17:275–81. 
44. Borghese F, Clanchy FI. CD74: An emerging 
opportunity as a therapeutic target in cancer and 
autoimmune disease. Expert Opin Ther Targets 
2011; 15:237–51. 
45. Stein R, Mattes MJ, Cardillo TM, Hansen HJ, Chang 
CH, Burton J, et al. CD74: A new candidate target 
for the immunotherapy of B-cell neoplasms. Clin 
Cancer Res 2007; 13:5556–63s.
46. Collins M, Ling V, Carreno BM. The B7 family of 
immune-regulatory ligands. Genome Biol 2005; 
6:223. 
47. Suvas S, Singh V, Sahdev S, Vohra H, Agrewala JN. 
Distinct role of CD80 and CD86 in the regulation of 
the activation of B cell and B cell lymphoma. J Biol 
Chem 2002; 277:7766–75.
48. Vyth-Dreese FA, Boot H, Dellemijn TA, Majoor DM, 
Oomen LC, Laman JD, et al. Localisation in situ of 
costimulatory molecules and cytokines in B-cell non-
Hodgkin’s lymphoma. Immunology 1998; 94:580–6.
49. Walsh SH, Rosenquist R. Immunoglobulin 
gene analysis of mature B-cell malignancies: 
Reconsideration of cellular origin and potential 
antigen involvement in pathogenesis. Med Oncol 
2005; 22:327–41. 
50. Jensen M, Tan G, Forman S, Wu AM, Raubitschek 
A. CD20 is a molecular target for scFvFc:zeta 
receptor redirected T cells: Implications for cellular 
immunotherapy of CD20+ malignancy. Biol Blood 
Marrow Transplant 1998; 4:75–83.
51. Brentjens RJ, Latouche JB, Santos E, Marti F, Gong 
MC, Lyddane C, et al. Eradication of systemic B-cell 
tumors by genetically targeted human T lymphocytes 
co-stimulated by CD80 and interleukin-15. Nat Med 
2003; 9:279–86. 
52. Chen EY, Press OW, Jensen MC. CD8 immuno-
magnetic selection and interleukin-15 (IL-15) 
facilitate the isolation of human CD8 cytotoxic 
T-lymphocytes (CTL) genetically engineered to 
express an anti-CD20 chimeric T-cell receptor 
(cTCR). J Clin Oncol 2004; 22:2542.
53. Wang J, Press OW, Lindgren CG, Greenberg P, 
Riddell S, Qian X, et al. Cellular immunotherapy 
for follicular lymphoma using genetically modified 
CD20-specific CD8+ cytotoxic T lymphocytes. Mol 
Ther 2004; 9:577–86. 
54. Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, 
Olivares S, Gonzalez N, et al. CD28 costimulation 
provided through a CD19-specific chimeric antigen 
receptor enhances in vivo persistence and antitumor 
efficacy of adoptively transferred T cells. Cancer Res 
2006; 66:10995–11004. 
55. Wang J, Jensen M, Lin Y, Sui X, Chen E, Lindgren 
CG, et al. Optimising adoptive polyclonal T cell 
immunotherapy of lymphomas, using a chimeric 
T cell receptor possessing CD28 and CD137 
costimulatory domains. Hum Gene Ther 2007; 
18:712–25. 
56. Milone MC, Fish JD, Carpenito C, Carroll RG, 
Binder GK, Teachey D, et al. Chimeric receptors 
containing CD137 signal transduction domains 
mediate enhanced  survival of T cells and increased 
antileukemic efficacy in vivo. Mol Ther 2009; 
17:1453–64. 
57. James SE, Greenberg PD, Jensen MC, Lin Y, Wang 
J, Till BG, et al. Antigen sensitivity of CD22-specific 
chimeric TCR is modulated by target epitope 
distance from the cell membrane. J Immunol 2008; 
180:7028–38.
58. Giordano Attianese GM, Marin V, Hoyos V, Savoldo 
B, Piszitola I, Tettamanti S, Agostoni V, et al. In 
vitro and in vivo model of a novel immunotherapy 
approach for chronic lymphocytic leukemia by 
anti-CD23 chimeric antigen receptor. Blood 2011; 
117:4736–45. 
59. Shaffer DR, Savoldo B, Yi Z, Chow KK, Kakarla S, 
Spencer DM, et al. T cells redirected against CD70 for 
the immunotherapy of CD70-positive malignancies. 
Blood 2011; 117:4304–14.  
60. Vera J, Savoldo B, Vigouroux S, Biagi E, Pule M, Rossig 
C, et al. T lymphocytes redirected against the kappa 
light chain of human immunoglobulin efficiently kill 
mature B lymphocyte-derived malignant cells. Blood 
Mohamed-Rachid Boulassel and Ahmed Galal
review | 285
2006; 108:3890–7. 
61. Wang L, Abbasi F, Gaigalas AK, Vogt RF, Marti 
GE. Comparison of fluorescein and phycoerythrin 
conjugates for quantifying CD20 expression on 
normal and leukemic B-cells. Cytometry B Clin 
Cytom 2006; 70:410–15. 
62. Rossmann ED, Lundin J, Lenkei R, Mellstedt H, 
Osterborg A. Variability in B-cell antigen expression: 
Implications for the treatment of B-cell lymphomas 
and leukemias with monoclonal antibodies. Hematol 
J 2001; 2:300–6.
63. Rocha B, Grandien A, Freitas AA. Anergy and 
exhaustion are independent mechanisms of 
peripheral T cell tolerance. J Exp Med 1995; 181:993–
1003.
64. Bataille R, Jégo G, Robillard N, Barillé-Nion S, 
Harousseau JL, Moreau P, et al. The phenotype 
of normal, reactive and malignant plasma cells. 
Identification of «many and multiple myelomas» and 
of new targets for myeloma therapy. Haematologica 
2006; 91:1234–340. 
65. Moloney M, Shreffler WG. Basic science for the 
practicing physician: flow cytometry and cell sorting. 
Ann Allergy Asthma Immunol 2008; 101:544–9.
66. Hombach AA, Schildgen V, Heuser C, Finnern R, 
Gilham DE, Abken H. T cell activation by antibody-
like immunoreceptors: the position of the binding 
epitope within the target molecule determines 
the efficiency of activation of redirected T cells. J 
Immunol 2007; 178:4650–7. 
67. Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen 
M, Debets R, et al. Treatment of metastatic renal 
cell carcinoma with autologous T-lymphocytes 
genetically retargeted against carbonic anhydrase IX: 
First clinical experience. J Clin Oncol 2006; 24:e20–
2. 
68. Morgan RA, Yang JC, Kitano M, Dudley ME, 
Laurencot CM, Rosenberg SA. Case report of a 
serious adverse event following the administration of 
T cells transduced with a chimeric antigen receptor 
recognising ERBB2. Mol Ther 2010; 18:843–51. 
69. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. 
Treatment of chronic lymphocytic leukemia with 
genetically targeted autologous T cells: Case report 
of an unforeseen adverse event in a phase I clinical 
trial. Mol Ther 2010; 18:666–8.
70. Lamers CH, Willemsen R, van Elzakker P, van 
Steenbergen-Langeveld S, Broertjes M, Oosterwijk-
Wakka J, et al. Immune responses to transgene and 
retroviral vector in patients treated with ex vivo-
engineered T cells. Blood 2011; 117:72–82.
71. Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, 
Kalos M, Ostberg JR, et al. Antitransgene rejection 
responses contribute to attenuated persistence of 
adoptively transferred CD20/CD19-specific chimeric 
antigen receptor redirected T cells in humans. Biol 
Blood Marrow Transplant 2010; 16:1245–56.
72. van Lunzen J, Glaunsinger T, Stahmer I, von Baehr 
V, Baum C, Schilz A, et al. Transfer of autologous 
gene-modified T cells in HIV-infected patients with 
advanced immunodeficiency and drug-resistant 
virus. Mol Ther 2007; 15:1024–33.
73. Newrzela S, Cornils K, Li Z, Baum C, Brugman MH, 
Hartmann M, et al. Resistance of mature T cells to 
oncogene transformation. Blood 2008; 112:2278–86.
74. Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, 
Wang GP, Berry CC, et al. Efficacy of gene therapy 
for X-linked severe combined immunodeficiency. N 
Engl J Med 2010; 363:355–64.
75. Junghans, RP. Strategy escalation: An emerging 
paradigm for safe clinical development of T cell gene 
therapies. J Transl Med 2010; 8:55. 
